Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07052903 · ClinicalTrials.gov registry record · Phase 3
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
A Phase 3 study of Transthyretin Amyloidosis With Cardiomyopathy, sponsored by Alnylam Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,250
- Enrollment target
- 20
- Study locations
NCT07052903 is a Phase 3 study of Transthyretin Amyloidosis With Cardiomyopathy that is actively recruiting participants, run by Alnylam Pharmaceuticals. The registered enrollment target is 1,250 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT07052903, a Phase 3 study of Transthyretin Amyloidosis With Cardiomyopathy, is actively recruiting participants, sponsored by Alnylam Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,250 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to: * Evaluate the efficacy of nucresiran compared to placebo on reducing all-cause mortality and cardiovascular (CV) events * Evaluate the efficacy of nucresiran compared to placebo on additional assessments of CV events and/or death * Evaluate the efficacy of nucresiran compared to placebo on patient-reported health status and health-related quality of life
Conditions Studied
Interventions
- DRUG Nucresiran
- DRUG Sterile Normal Saline (0.9% NaCl)
Study Locations (20)
Georgia
- Clinical Trial Site - Atlanta
- Clinical Trial Site - Gainesville
- Clinical Trial Site - Tucker
New York
- Clinical Trial Site - Manhasset
- Clinical Trial Site - New York
- Clinical Trial Site - The Bronx
Indiana
- Clinical Trial Site - Indianapolis
- Clinical Trial Site - Indianapolis
Pennsylvania
- Clinical Trial Site - Lancaster
- Clinical Trial Site - Philadelphia
California
- Clinical Trial Site - La Jolla
District of Columbia
- Clinical Trial Site - Washington D.C.
Florida
- Clinical Trial Site - Brandon
Kansas
- Clinical Trial Site - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,250 participants |
| Start Date | 2025-07-02 |
| Est. Completion | 2032-11-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07052903
The ClinicalTrials.gov registry entry for NCT07052903 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alnylam Pharmaceuticals, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Transthyretin Amyloidosis With Cardiomyopathy appearing as the primary indexed condition, and to 2 interventions - of which Nucresiran is the first listed.
NCT07052903 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Georgia, New York, Indiana.
Frequently Asked Questions
What is clinical trial NCT07052903 about?
NCT07052903 is a clinical study titled "TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy". The purpose of this study is to: * Evaluate the efficacy of nucresiran compared to placebo on reducing all-cause mortality and cardiovascular (CV) events * Evaluate the efficacy of nucresiran compared to placebo on additional assessments of CV events and/or death * Evaluate the efficacy of nucresir...
What is the current status of trial NCT07052903?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,250 participants. The study started on 2025-07-02. Estimated completion is 2032-11-30.
What conditions does trial NCT07052903 study?
This clinical trial studies the following conditions: Transthyretin Amyloidosis With Cardiomyopathy.
What interventions are being tested in trial NCT07052903?
The interventions under investigation include: Nucresiran (DRUG), Sterile Normal Saline (0.9% NaCl) (DRUG).
Who is sponsoring clinical trial NCT07052903?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07052903 being conducted?
This trial has 20 study locations across California, District of Columbia, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Transthyretin Amyloidosis With Cardiomyopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.